DAYTON, Ohio and CINCINNATI, Aug. 16, 2016 – Brixey & Meyer Capital (“BMC”) announced today it has held its final closing of the BMC Growth Fund, LLC.  This final closing held on July 18, 2016 resulted in total commitments of approximately $18.0 million.  The fund’s investors are made up of successful entrepreneurs and private investors predominately from Southwest Ohio.

The fund was launched in November 2015 in conjunction with the first acquisition of the fund, Clinical Research Solutions.  Clinical Research Solutions (“CRS”) is headquartered in Cleveland, Ohio with locations throughout Ohio and Tennessee.  CRS performs phase I to IV clinical trials for large and small pharmaceutical companies across the world.

BMC, with its first fund, targets investments in lower middle market companies generating $1 to $3 million of cash flow.  While BMC considers investments in a wide range of industries, they generally focus on healthcare, distribution, manufacturing and services related industries.  BMC expects to add two or more companies to the fund over the next year.

“We could not be happier with the group of investors in our fund,” said David Brixey, Managing Director of Brixey & Meyer Capital, “many of our investors are entrepreneurs themselves that believe in our philosophy in this space.  It is truly powerful.”

BMC relates the success of the fund to the disciplined investment philosophy of Brixey & Meyer Capital’s investment committee.  This committee is made up of accomplished business owners, operators and entrepreneurs including David Brixey,Harry Loyle, Doug Meyer, Patrick Rini, Michael Shane, Chip Turner and Darrick Zucco.